##gff-version 3
##sequence-region P60484 1 403
P60484	UniProtKB	Initiator methionine	1	1	.	.	.	Note=Removed;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:22814378;Dbxref=PMID:22814378	
P60484	UniProtKB	Chain	2	403	.	.	.	ID=PRO_0000215904;Note=Phosphatidylinositol 3%2C4%2C5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN	
P60484	UniProtKB	Domain	14	185	.	.	.	Note=Phosphatase tensin-type;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00590	
P60484	UniProtKB	Domain	190	350	.	.	.	Note=C2 tensin-type;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00589	
P60484	UniProtKB	Region	338	348	.	.	.	Note=Required for interaction with NOP53;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15355975;Dbxref=PMID:15355975	
P60484	UniProtKB	Region	401	403	.	.	.	Note=PDZ domain-binding	
P60484	UniProtKB	Active site	124	124	.	.	.	Note=Phosphocysteine intermediate;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00590	
P60484	UniProtKB	Modified residue	2	2	.	.	.	Note=N-acetylthreonine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:22814378;Dbxref=PMID:22814378	
P60484	UniProtKB	Modified residue	294	294	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:O08586	
P60484	UniProtKB	Modified residue	336	336	.	.	.	Note=Phosphotyrosine%3B by FRK;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19345329;Dbxref=PMID:19345329	
P60484	UniProtKB	Modified residue	366	366	.	.	.	Note=Phosphothreonine%3B by GSK3-beta and PLK3;Ontology_term=ECO:0000244,ECO:0000269,ECO:0000269;evidence=ECO:0000244|PubMed:24275569,ECO:0000269|PubMed:12297295,ECO:0000269|PubMed:20940307;Dbxref=PMID:24275569,PMID:12297295,PMID:20940307	
P60484	UniProtKB	Modified residue	370	370	.	.	.	Note=Phosphoserine%3B by CK2 and PLK3;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11035045,ECO:0000269|PubMed:12297295,ECO:0000269|PubMed:20940307;Dbxref=PMID:11035045,PMID:12297295,PMID:20940307	
P60484	UniProtKB	Modified residue	380	380	.	.	.	Note=Phosphoserine%3B by ROCK1 and CK2;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11035045;Dbxref=PMID:11035045	
P60484	UniProtKB	Modified residue	382	382	.	.	.	Note=Phosphothreonine%3B by ROCK1 and CK2;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11035045;Dbxref=PMID:11035045	
P60484	UniProtKB	Modified residue	383	383	.	.	.	Note=Phosphothreonine%3B by ROCK1 and CK2;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11035045;Dbxref=PMID:11035045	
P60484	UniProtKB	Modified residue	385	385	.	.	.	Note=Phosphoserine%3B by CK2;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11035045,ECO:0000269|PubMed:12297295;Dbxref=PMID:11035045,PMID:12297295	
P60484	UniProtKB	Modified residue	401	401	.	.	.	Note=Phosphothreonine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10646847;Dbxref=PMID:10646847	
P60484	UniProtKB	Cross-link	13	13	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin);Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18716620;Dbxref=PMID:18716620	
P60484	UniProtKB	Cross-link	289	289	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin);Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18716620;Dbxref=PMID:18716620	
P60484	UniProtKB	Alternative sequence	1	1	.	.	.	ID=VSP_055420;Note=In isoform alpha. M->MERGGEAAAAAAAAAAAPGRGSESPVTISRAGNAGELVSPLLLPPTRRRRRRHIQGPGPVLNLPSAAAAPPVARAPEAAGGGSRSEDYSSSPHSAAAAARPLAAEEKQAQSLQPSSSRRSSHYPAAVQSQAAAERGASATAKSRAISILQKKPRHQQLLPSLSSFFFSHRLPDM;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P60484	UniProtKB	Alternative sequence	55	70	.	.	.	ID=VSP_055421;Note=In isoform 3. RFLDSKHKNHYKIYNL->S;Ontology_term=ECO:0000303;evidence=ECO:0000303|Ref.7	
P60484	UniProtKB	Alternative sequence	165	190	.	.	.	ID=VSP_055422;Note=In isoform 3. GVTIPSQRRYVYYYSYLLKNHLDYRP->ADPTGGIPDKGIIVIGDGSSMDVIAP;Ontology_term=ECO:0000303;evidence=ECO:0000303|Ref.7	
P60484	UniProtKB	Alternative sequence	191	403	.	.	.	ID=VSP_055423;Note=In isoform 3. Missing;Ontology_term=ECO:0000303;evidence=ECO:0000303|Ref.7	
P60484	UniProtKB	Natural variant	10	10	.	.	.	ID=VAR_026248;Note=Retains phosphatase activity towards Ins(1%2C3%2C4%2C5)P4 and PtdIns(3%2C4%2C5)P3%3B retains the ability to bind phospholipid membranes. S->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=PMID:10866302	
P60484	UniProtKB	Natural variant	15	15	.	.	.	ID=VAR_007457;Note=In glioma. R->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9090379;Dbxref=dbSNP:rs1064794096,PMID:9090379	
P60484	UniProtKB	Natural variant	16	16	.	.	.	ID=VAR_026249;Note=Loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4%3B retains the ability to bind phospholipid membranes. Y->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=PMID:10866302	
P60484	UniProtKB	Natural variant	19	19	.	.	.	ID=VAR_018100;Note=In malignant melanoma%3B somatic mutation. D->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10978354;Dbxref=dbSNP:rs121909233,PMID:10978354	
P60484	UniProtKB	Natural variant	20	20	.	.	.	ID=VAR_026250;Note=Reduced phosphatase activity towards Ins(1%2C3%2C4%2C5)P4%3B retains phosphatase activity towards PtdIns(3%2C4%2C5)P3. G->E;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=dbSNP:rs1064795967,PMID:10866302	
P60484	UniProtKB	Natural variant	27	27	.	.	.	ID=VAR_026251;Note=Loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. Y->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=dbSNP:rs886041877,PMID:10866302	
P60484	UniProtKB	Natural variant	33	33	.	.	.	ID=VAR_008733;Note=In CWS1. Missing;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10234502;Dbxref=PMID:10234502	
P60484	UniProtKB	Natural variant	34	34	.	.	.	ID=VAR_008734;Note=In CWS1. A->D;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10400993,ECO:0000269|PubMed:11494117;Dbxref=PMID:10400993,PMID:11494117	
P60484	UniProtKB	Natural variant	35	35	.	.	.	ID=VAR_008036;Note=In CWS1. M->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9425889;Dbxref=dbSNP:rs121909225,PMID:9425889	
P60484	UniProtKB	Natural variant	36	36	.	.	.	ID=VAR_007458;Note=In glioma. G->E;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9090379;Dbxref=PMID:9090379	
P60484	UniProtKB	Natural variant	36	36	.	.	.	ID=VAR_026252;Note=In endometrial hyperplasia. G->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9635567;Dbxref=dbSNP:rs786204854,PMID:9635567	
P60484	UniProtKB	Natural variant	42	42	.	.	.	ID=VAR_007459;Note=In glioma%3B retains phosphatase activity towards Ins(1%2C3%2C4%2C5)P4 and PtdIns(3%2C4%2C5)P3%3B retains the ability to bind phospholipid membranes. L->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9090379;Dbxref=PMID:9090379	
P60484	UniProtKB	Natural variant	47	47	.	.	.	ID=VAR_011587;Note=In CWS1. R->G;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11494117;Dbxref=dbSNP:rs786204855,PMID:11494117	
P60484	UniProtKB	Natural variant	57	57	.	.	.	ID=VAR_007460;Note=In glioma%3B loss of protein phosphatase activity. L->W;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:9090379,ECO:0000269|PubMed:9256433;Dbxref=dbSNP:rs786202398,PMID:9090379,PMID:9256433	
P60484	UniProtKB	Natural variant	61	61	.	.	.	ID=VAR_018101;Note=Foun in a patient with macrocephaly%2C ventriculomegaly%2C vertebral anomalies%2C anal atresia%2C congenital cardiac disease%2C tracheoesophageal fistula%2C renal anomalies%2C radial dysplasia and other limb defects%3B unknown pathological significance. H->D;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11748304;Dbxref=dbSNP:rs121909236,PMID:11748304	
P60484	UniProtKB	Natural variant	61	61	.	.	.	ID=VAR_026253;Note=Loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. H->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=dbSNP:rs398123316,PMID:10866302	
P60484	UniProtKB	Natural variant	65	403	.	.	.	ID=VAR_078705;Note=In MCEPHAS. Missing;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:26637798;Dbxref=PMID:26637798	
P60484	UniProtKB	Natural variant	67	67	.	.	.	ID=VAR_007461;Note=In CWS1. I->R	
P60484	UniProtKB	Natural variant	68	68	.	.	.	ID=VAR_007462;Note=In CWS1%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4 and PtdIns(3%2C4%2C5)P3%3B retains the ability to bind phospholipid membranes. Y->H;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10400993,ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:11494117,ECO:0000269|PubMed:9600246;Dbxref=dbSNP:rs398123317,PMID:10400993,PMID:10866302,PMID:11494117,PMID:9600246	
P60484	UniProtKB	Natural variant	70	70	.	.	.	ID=VAR_018102;Note=In CWS1. L->P;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9832031;Dbxref=dbSNP:rs121909226,PMID:9832031	
P60484	UniProtKB	Natural variant	71	71	.	.	.	ID=VAR_026254;Note=In CWS1%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. C->Y;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=PMID:10866302	
P60484	UniProtKB	Natural variant	93	93	.	.	.	ID=VAR_032634;Note=In MCEPHAS. H->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15805158;Dbxref=dbSNP:rs121909238,PMID:15805158	
P60484	UniProtKB	Natural variant	93	93	.	.	.	ID=VAR_026255;Note=In CWS1. H->Y;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=PMID:10866302	
P60484	UniProtKB	Natural variant	105	105	.	.	.	ID=VAR_026256;Note=In CWS1%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. C->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=PMID:10866302	
P60484	UniProtKB	Natural variant	105	105	.	.	.	ID=VAR_008735;Note=In CWS1. C->Y;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10400993,ECO:0000269|PubMed:11494117;Dbxref=dbSNP:rs587782343,PMID:10400993,PMID:11494117	
P60484	UniProtKB	Natural variant	107	107	.	.	.	ID=VAR_026257;Note=In CWS1 and glioblastoma%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. D->Y;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:9331071;Dbxref=PMID:10866302,PMID:9331071	
P60484	UniProtKB	Natural variant	112	112	.	.	.	ID=VAR_007807;Note=In CWS1 and LDD%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. L->P;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10051160,ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:9600246;Dbxref=dbSNP:rs121909230,PMID:10051160,PMID:10866302,PMID:9600246	
P60484	UniProtKB	Natural variant	112	112	.	.	.	ID=VAR_026258;Note=Loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. L->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=PMID:10866302	
P60484	UniProtKB	Natural variant	119	119	.	.	.	ID=VAR_011588;Note=In multiple cancers. V->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10807691;Dbxref=dbSNP:rs139767111,PMID:10807691	
P60484	UniProtKB	Natural variant	121	121	.	.	.	ID=VAR_018103;Note=In HNSCC. A->G;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11801303;Dbxref=dbSNP:rs121909237,PMID:11801303	
P60484	UniProtKB	Natural variant	121	121	.	.	.	ID=VAR_026259;Note=In glioblastoma%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. A->P;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:9331071;Dbxref=PMID:10866302,PMID:9331071	
P60484	UniProtKB	Natural variant	123	123	.	.	.	ID=VAR_007463;Note=In CWS1. H->R;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10234502,ECO:0000269|PubMed:9259288;Dbxref=dbSNP:rs121909222,PMID:10234502,PMID:9259288	
P60484	UniProtKB	Natural variant	123	123	.	.	.	ID=VAR_026260;Note=In endometrial cancer%3B loss of protein phosphatase activity. H->Y;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9256433;Dbxref=dbSNP:rs786204931,PMID:9256433	
P60484	UniProtKB	Natural variant	124	124	.	.	.	ID=VAR_007464;Note=In CWS1. C->R;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10234502,ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:9259288;Dbxref=dbSNP:rs121909223,PMID:10234502,PMID:10866302,PMID:9259288	
P60484	UniProtKB	Natural variant	124	124	.	.	.	ID=VAR_018104;Note=In CWS1%3B phosphatase-dead protein with neither lipid nor protein phosphatase activity. C->S;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11230179,ECO:0000269|PubMed:9811831;Dbxref=PMID:11230179,PMID:9811831	
P60484	UniProtKB	Natural variant	126	126	.	.	.	ID=VAR_076551;Note=In a patient with prostate cancer%3B reduced phosphatase activity towards PtdIns(3%2C4%2C5)%3B shifts its activity from phosphatidylinositol phosphate 3-phosphatase to phosphatidylinositol phosphate 5-phosphatase%3B disrupts PI3K/ATK signaling%3B reduced cell migration. A->G;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:26504226;Dbxref=PMID:26504226	
P60484	UniProtKB	Natural variant	129	129	.	.	.	ID=VAR_007465;Note=In CWS1%3B no lipid phosphatase activity but retains protein phosphatase activity%3B retains ability to inhibit focal adhesion formation. G->E;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:11230179,ECO:0000269|PubMed:9140396,ECO:0000269|PubMed:9616126,ECO:0000269|PubMed:9811831;Dbxref=dbSNP:rs121909218,PMID:10866302,PMID:11230179,PMID:9140396,PMID:9616126,PMID:9811831	
P60484	UniProtKB	Natural variant	129	129	.	.	.	ID=VAR_007466;Note=In glioblastoma%3B severely reduced protein phosphatase activity%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. G->R;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:9072974,ECO:0000269|PubMed:9256433,ECO:0000269|PubMed:9331071;Dbxref=dbSNP:rs786204929,PMID:10866302,PMID:9072974,PMID:9256433,PMID:9331071	
P60484	UniProtKB	Natural variant	130	130	.	.	.	ID=VAR_026261;Note=Loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4 and PtdIns(3%2C4%2C5)P3. R->G;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=dbSNP:rs121909224,PMID:10866302	
P60484	UniProtKB	Natural variant	130	130	.	.	.	ID=VAR_007467;Note=In CWS1 and endometrial hyperplasia%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4%3B retains ability to bind phospholipid membranes. R->L;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:9635567;Dbxref=dbSNP:rs121909229,PMID:10866302,PMID:9635567	
P60484	UniProtKB	Natural variant	130	130	.	.	.	ID=VAR_007468;Note=In CWS1%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4%3B retains ability to bind phospholipid membranes. R->Q;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:9915974;Dbxref=dbSNP:rs121909229,PMID:10866302,PMID:9915974	
P60484	UniProtKB	Natural variant	131	131	.	.	.	ID=VAR_076762;Note=In MCEPHAS. T->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23160955;Dbxref=dbSNP:rs397514560,PMID:23160955	
P60484	UniProtKB	Natural variant	132	132	.	.	.	ID=VAR_032635;Note=In one patient with clinical findings suggesting hamartoma tumor syndrome. G->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16752378;Dbxref=dbSNP:rs121909241,PMID:16752378	
P60484	UniProtKB	Natural variant	133	133	.	.	.	ID=VAR_026262;Note=Loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P3. V->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=PMID:10866302	
P60484	UniProtKB	Natural variant	134	134	.	.	.	ID=VAR_007469;Note=In prostate cancer%3B no effect on protein phosphatase activity%3B reduced phosphatase activity towards Ins(1%2C3%2C4%2C5)P3 but retains PtdIns(3%2C4%2C5)P3 phosphatase activity. M->L;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:9072974,ECO:0000269|PubMed:9256433;Dbxref=PMID:10866302,PMID:9072974,PMID:9256433	
P60484	UniProtKB	Natural variant	135	135	.	.	.	ID=VAR_008736;Note=In CWS1. I->V;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10400993,ECO:0000269|PubMed:11494117;Dbxref=dbSNP:rs587782360,PMID:10400993,PMID:11494117	
P60484	UniProtKB	Natural variant	136	136	.	.	.	ID=VAR_007808;Note=In CWS1%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P3. C->Y;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:9735393;Dbxref=dbSNP:rs786204859,PMID:10866302,PMID:9735393	
P60484	UniProtKB	Natural variant	137	137	.	.	.	ID=VAR_008737;Note=In CWS1. A->AN;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9345101;Dbxref=PMID:9345101	
P60484	UniProtKB	Natural variant	155	155	.	.	.	ID=VAR_026263;Note=In CWS1%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. Y->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=dbSNP:rs1060500126,PMID:10866302	
P60484	UniProtKB	Natural variant	158	158	.	.	.	ID=VAR_011589;Note=In multiple cancers. V->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10807691;Dbxref=PMID:10807691	
P60484	UniProtKB	Natural variant	165	165	.	.	.	ID=VAR_008739;Note=In CWS1. G->E;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10234502;Dbxref=PMID:10234502	
P60484	UniProtKB	Natural variant	165	165	.	.	.	ID=VAR_026264;Note=In glioblastoma%3B severely reduced protein phosphatase activity%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4%3B retains ability to bind phospholipid membranes. G->R;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:9256433,ECO:0000269|PubMed:9331071;Dbxref=dbSNP:rs587782603,PMID:10866302,PMID:9256433,PMID:9331071	
P60484	UniProtKB	Natural variant	165	165	.	.	.	ID=VAR_008738;Note=In CWS1. G->V;Dbxref=dbSNP:rs786204863	
P60484	UniProtKB	Natural variant	167	167	.	.	.	ID=VAR_076763;Note=In MCEPHAS. T->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23160955;Dbxref=dbSNP:rs397514559,PMID:23160955	
P60484	UniProtKB	Natural variant	167	167	.	.	.	ID=VAR_026265;Note=In breast cancer%3B severely reduced protein phosphatase activity. T->P;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9256433;Dbxref=PMID:9256433	
P60484	UniProtKB	Natural variant	170	170	.	.	.	ID=VAR_026266;Note=Loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4%3B retains ability to bind phospholipid membranes. S->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=PMID:10866302	
P60484	UniProtKB	Natural variant	170	170	.	.	.	ID=VAR_007470;Note=In CWS1%3B severely reduced protein phosphatase activity%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. S->R;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10400993,ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:11494117,ECO:0000269|PubMed:9241266,ECO:0000269|PubMed:9256433;Dbxref=dbSNP:rs121909221,PMID:10400993,PMID:10866302,PMID:11494117,PMID:9241266,PMID:9256433	
P60484	UniProtKB	Natural variant	173	173	.	.	.	ID=VAR_026267;Note=In endometrial hyperplasia%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4 and PtdIns(3%2C4%2C5)P3%3B retains ability to bind phospholipid membranes. R->C;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:9635567;Dbxref=dbSNP:rs121913293,PMID:10866302,PMID:9635567	
P60484	UniProtKB	Natural variant	173	173	.	.	.	ID=VAR_026268;Note=Loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. R->H;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=dbSNP:rs121913294,PMID:10866302	
P60484	UniProtKB	Natural variant	173	173	.	.	.	ID=VAR_026269;Note=Loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. R->P;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=dbSNP:rs121913294,PMID:10866302	
P60484	UniProtKB	Natural variant	174	174	.	.	.	ID=VAR_026270;Note=Loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. Y->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=dbSNP:rs587782316,PMID:10866302	
P60484	UniProtKB	Natural variant	191	191	.	.	.	ID=VAR_026271;Note=In endometrial hyperplasia. V->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9635567;Dbxref=PMID:9635567	
P60484	UniProtKB	Natural variant	217	217	.	.	.	ID=VAR_018105;Note=In malignant melanoma%3B somatic mutation. V->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10978354;Dbxref=dbSNP:rs121909234,PMID:10978354	
P60484	UniProtKB	Natural variant	227	227	.	.	.	ID=VAR_026272;Note=Reduced phosphatase activity towards Ins(1%2C3%2C4%2C5)P4 but retains PtdIns(3%2C4%2C5)P3 phosphatase activity. S->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=dbSNP:rs905615413,PMID:10866302	
P60484	UniProtKB	Natural variant	234	234	.	.	.	ID=VAR_018106;Note=In GLM2%3B the patient also suffered from benign meningioma%3B not capable of inducing apoptosis%3B induced increased cell proliferation%3B led to high constitutive AKT1 activation which could not be increased further by stimulation with insulin. R->Q;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12085208;Dbxref=dbSNP:rs121909235,PMID:12085208	
P60484	UniProtKB	Natural variant	241	241	.	.	.	ID=VAR_032636;Note=In MCEPHAS. F->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15805158;Dbxref=dbSNP:rs121909240,PMID:15805158	
P60484	UniProtKB	Natural variant	246	246	.	.	.	ID=VAR_008740;Note=In CWS1. P->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10400993;Dbxref=dbSNP:rs587782350,PMID:10400993	
P60484	UniProtKB	Natural variant	251	251	.	.	.	ID=VAR_026273;Note=Loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4%3B retains ability to bind phospholipid membranes. G->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=PMID:10866302	
P60484	UniProtKB	Natural variant	252	252	.	.	.	ID=VAR_032637;Note=In MCEPHAS. D->G;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15805158;Dbxref=dbSNP:rs121909239,PMID:15805158	
P60484	UniProtKB	Natural variant	289	289	.	.	.	ID=VAR_008741;Note=In CWS1%3B reduced phosphatase activity towards Ins(1%2C3%2C4%2C5)P4%3B retains ability to bind phospholipid membranes%3B predominantly nuclear. K->E;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:18716620,ECO:0000269|PubMed:9797362;Dbxref=dbSNP:rs562015640,PMID:10866302,PMID:18716620,PMID:9797362	
P60484	UniProtKB	Natural variant	290	290	.	.	.	ID=VAR_025167;Note=V->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|Ref.10;Dbxref=dbSNP:rs35600253	
P60484	UniProtKB	Natural variant	319	319	.	.	.	ID=VAR_026274;Note=In glioma%3B reduced tumor suppressor activity%3B fails to inactivate AKT/PKB. Missing;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10468583,ECO:0000269|PubMed:9090379;Dbxref=PMID:10468583,PMID:9090379	
P60484	UniProtKB	Natural variant	331	331	.	.	.	ID=VAR_026275;Note=In CWS1%3B reduced phosphatase activity towards Ins(1%2C3%2C4%2C5)P4%3B retains ability to bind phospholipid membranes. D->G;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=PMID:10866302	
P60484	UniProtKB	Natural variant	341	341	.	.	.	ID=VAR_026276;Note=In CWS1%3B loss of interaction with NOP53%3B decreased phosphorylation at S-380%3B decreased stability%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. F->V;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:15355975;Dbxref=PMID:10866302,PMID:15355975	
P60484	UniProtKB	Natural variant	342	342	.	.	.	ID=VAR_026277;Note=In CWS1%3B reduced phosphatase activity towards Ins(1%2C3%2C4%2C5)P4 but PtdIns(3%2C4%2C5)P3 phosphatase activity is similar to wild-type. K->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=dbSNP:rs398123314,PMID:10866302	
P60484	UniProtKB	Natural variant	343	343	.	.	.	ID=VAR_008742;Note=In CWS1%3B loss of interaction with NOP53%3B decreased phosphorylation at S-380%3B decreased stability%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. V->E;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:15355975,ECO:0000269|PubMed:9399897;Dbxref=PMID:10866302,PMID:15355975,PMID:9399897	
P60484	UniProtKB	Natural variant	345	345	.	.	.	ID=VAR_026278;Note=In glioblastoma%3B reduced tumor suppressor activity%3B loss of interaction with NOP53%3B decreased phosphorylation at S-380%3B decreased stability%3B loss of phosphatase activity towards Ins(1%2C3%2C4%2C5)P4%3B reduced ability to inactivate AKT/PKB%3B retains ability to bind phospholipid membranes. L->Q;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10468583,ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:15355975,ECO:0000269|PubMed:9331071;Dbxref=PMID:10468583,PMID:10866302,PMID:15355975,PMID:9331071	
P60484	UniProtKB	Natural variant	347	347	.	.	.	ID=VAR_008743;Note=In CWS1%3B reduced phosphatase activity towards Ins(1%2C3%2C4%2C5)P4. F->L;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10866302,ECO:0000269|PubMed:9399897;Dbxref=PMID:10866302,PMID:9399897	
P60484	UniProtKB	Natural variant	348	348	.	.	.	ID=VAR_026279;Note=In endometrial hyperplasia%3B reduced phosphatase activity towards PtdIns(3%2C4%2C5)P3%3B mildly reduced tumor suppressor activity%3B reduced ability to inactivate AKT/PKB. T->I;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10468583,ECO:0000269|PubMed:9635567;Dbxref=PMID:10468583,PMID:9635567	
P60484	UniProtKB	Natural variant	369	369	.	.	.	ID=VAR_026280;Note=Retains Ins(1%2C3%2C4%2C5)P4 and PtdIns(3%2C4%2C5)P3 phosphatase activity%3B retains ability to bind phospholipid membranes. V->G;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=PMID:10866302	
P60484	UniProtKB	Natural variant	401	401	.	.	.	ID=VAR_026281;Note=Retains Ins(1%2C3%2C4%2C5)P4 and PtdIns(3%2C4%2C5)P3 phosphatase activity%3B retains ability to bind phospholipid membranes. T->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10866302;Dbxref=PMID:10866302	
P60484	UniProtKB	Mutagenesis	1	1	.	.	.	Note=Expression is restricted to isoform alpha. M->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:24768297;Dbxref=PMID:24768297	
P60484	UniProtKB	Mutagenesis	13	13	.	.	.	Note=Nuclear. Cytoplasmic%3B when associated with E-289. Shows less tumor suppressive ability%3B when associated with E-289. K->E;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18716620;Dbxref=PMID:18716620	
P60484	UniProtKB	Mutagenesis	92	92	.	.	.	Note=700-fold reduction in phosphatase activity towards PtdIns(3%2C4%2C5)P3. Loss of protein phosphatase activity. Unable to inhibit focal adhesion formation. D->A;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10555148,ECO:0000269|PubMed:9616126;Dbxref=PMID:10555148,PMID:9616126	
P60484	UniProtKB	Mutagenesis	93	93	.	.	.	Note=75%25 reduction in phosphatase activity towards PtdIns(3%2C4%2C5)P3. Modest reduction in phosphatase activity towards PtdIns(3%2C4)P2. H->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10555148;Dbxref=PMID:10555148	
P60484	UniProtKB	Mutagenesis	124	124	.	.	.	Note=Loss of protein phosphatase activity. Unable to inhibit focal adhesion formation. C->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9616126;Dbxref=PMID:9616126	
P60484	UniProtKB	Mutagenesis	125	125	.	.	.	Note=Reduced phosphatase activity towards PtdIns(3%2C4%2C5)P3%2C PtdIns(3%2C4)P2 and PtdIns(3)P. K->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10555148;Dbxref=PMID:10555148	
P60484	UniProtKB	Mutagenesis	126	126	.	.	.	Note=Does not reduce phosphatase activity towards PtdIns(3%2C4%2C5)P3 and PtdIns(3%2C4)P2. A->P;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:26504226;Dbxref=PMID:26504226	
P60484	UniProtKB	Mutagenesis	126	126	.	.	.	Note=Does not reduce phosphatase activity towards PtdIns(3%2C4%2C5)P3 and PtdIns(3%2C4)P2. A->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:26504226;Dbxref=PMID:26504226	
P60484	UniProtKB	Mutagenesis	126	126	.	.	.	Note=Does not reduce phosphatase activity towards PtdIns(3%2C4%2C5)P3 and PtdIns(3%2C4)P2. A->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:26504226;Dbxref=PMID:26504226	
P60484	UniProtKB	Mutagenesis	128	128	.	.	.	Note=85%25 reduction in phosphatase activity towards PtdIns(3%2C4%2C5)P3. K->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10555148;Dbxref=PMID:10555148	
P60484	UniProtKB	Mutagenesis	128	128	.	.	.	Note=Does not reduce phosphatase activity towards PtdIns(3%2C4%2C5)P3. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10555148;Dbxref=PMID:10555148	
P60484	UniProtKB	Mutagenesis	130	130	.	.	.	Note=Does not affect the ability to inhibit AKT/PKB activation. R->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9811831;Dbxref=PMID:9811831	
P60484	UniProtKB	Mutagenesis	167	167	.	.	.	Note=60%25 reduction in phosphatase activity towards PtdIns(3%2C4%2C5)P3. T->A%2CD;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10555148;Dbxref=PMID:10555148	
P60484	UniProtKB	Mutagenesis	171	171	.	.	.	Note=75%25 reduction in phosphatase activity towards PtdIns(3%2C4%2C5)P3. Q->A%2CE;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10555148;Dbxref=PMID:10555148	
P60484	UniProtKB	Mutagenesis	263	269	.	.	.	Note=Reduces the growth suppression activity and cells show anchorage-independent growth. Reduces binding to phospholipid membranes in vitro. Phosphatase activity towards PtdIns(3%2C4%2C5)P3 is not affected. KMLKKDK->AAGAADA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10555148;Dbxref=PMID:10555148	
P60484	UniProtKB	Mutagenesis	289	289	.	.	.	Note=Cytoplasmic%3B when associated with E-13. Shows less tumor suppressive ability%3B when associated with E-13. K->E;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18716620;Dbxref=PMID:18716620	
P60484	UniProtKB	Mutagenesis	327	335	.	.	.	Note=Reduces growth suppression activity and promotes anchorage-independent growth. Reduces binding to phospholipid membranes in vitro%3B phosphatase activity towards PtdIns(3%2C4%2C5)P3 is not affected. KANKDKANR->AAGADAANA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10555148;Dbxref=PMID:10555148	
P60484	UniProtKB	Mutagenesis	336	336	.	.	.	Note=Significantly lower phosphatase activity%2C reduced protein stability and decreased growth-inhibitory effect. Y->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19345329;Dbxref=PMID:19345329	
P60484	UniProtKB	Mutagenesis	366	366	.	.	.	Note=Decreased stability. T->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20940307;Dbxref=PMID:20940307	
P60484	UniProtKB	Mutagenesis	370	370	.	.	.	Note=Decreased stability. S->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20940307;Dbxref=PMID:20940307	
P60484	UniProtKB	Mutagenesis	401	401	.	.	.	Note=Loss of DLG1-binding. No effect on MAGI2- and MAST2-binding. T->A	
P60484	UniProtKB	Mutagenesis	402	402	.	.	.	Note=No effect on MAGI2-%2C MAST2- and DLG1-binding. K->A	
P60484	UniProtKB	Mutagenesis	402	402	.	.	.	Note=Loss of DLG1-%2C MAGI2-%2C MAGI3- and MAST2-binding. Decrease of protein stability. K->W	
P60484	UniProtKB	Mutagenesis	403	403	.	.	.	Note=Loss of DLG1-%2C MAGI2-%2C MAGI3-%2C MAST1-%2C MAST2- and MAST3-binding. V->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15951562;Dbxref=PMID:15951562	
P60484	UniProtKB	Turn	19	22	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	23	29	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	32	35	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	39	41	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	44	47	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5BZZ	
P60484	UniProtKB	Helix	50	60	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	61	63	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	65	73	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Helix	78	80	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5BZZ	
P60484	UniProtKB	Beta strand	81	83	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5BZZ	
P60484	UniProtKB	Beta strand	85	90	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Helix	98	100	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Helix	101	112	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Turn	113	115	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	118	123	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	125	128	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Helix	129	141	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Helix	148	159	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	161	163	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Helix	169	184	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	192	202	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	206	209	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5BZZ	
P60484	UniProtKB	Beta strand	213	219	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	222	226	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	232	235	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	238	259	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	262	264	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5BZZ	
P60484	UniProtKB	Beta strand	268	276	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Helix	277	279	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	280	284	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5BZZ	
P60484	UniProtKB	Beta strand	310	312	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5BZX	
P60484	UniProtKB	Beta strand	315	321	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Helix	322	324	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Helix	328	330	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	335	337	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	342	349	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1D5R	
P60484	UniProtKB	Beta strand	395	403	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2KYL	
